Company / Free Cash Flow per Share
RAPT Therapeutics, Inc. Free Cash Flow per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$2.05
FY2024
5-year range
-$2.56 / -$1.69
FY2020-FY2024
Trend
+20.1%
vs FY2023
Sector context
#135 of 191
Health Care
What the data says
At $-2.05, RAPT Therapeutics, Inc.'s free cash flow per share ranks #135 of 191 in the Health Care sector. Free Cash Flow per Share has fluctuated over the past 7 years, ranging from $-58.58 in FY2018 to $-1.69 in FY2020.
Based on SEC 10-K filings.
-2.05 in FY2024.
Improved from $-2.20 to $-2.05 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#135 of 191 in Health CareTop 71% of 191This company -$2.05 Sector average -$24.68
▼
+91.7% above sector average
Key checks
Key Insights
- In FY2024, free cash flow per share increased 20.1% year-over-year.
- Ranks #135 out of 191 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2020.
- Lowest free cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.05 | +20.1% |
| FY2023 | -$2.56 | -16.4% |
| FY2022 | -$2.20 | +2.4% |
| FY2021 | -$2.26 | -33.1% |
| FY2020 | -$1.69 | +79.7% |
| FY2019 | -$8.37 | +85.7% |
| FY2018 | -$58.58 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026